We are live on ! Find out more
ACM

ACT Capital Management Portfolio holdings

AUM $153M
This Fund
S&P 500
This Quarter Est. Return
-15.2%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$138M
AUM Growth
-$54.6M
Cap. Flow
-$14.6M
Cap. Flow %
-10.54%
Top 10 Hldgs %
60.84%
Holding
122
New
13
Increased
15
Reduced
28
Closed
30

Top Buys

Rank Stock Value
1
META icon
Meta Platforms (Facebook)
META
+$2.49M
2
ADTN icon
Adtran
ADTN
+$2.33M
3
VIR icon
Vir Biotechnology
VIR
+$2.27M
4
SSYS icon
Stratasys
SSYS
+$1.84M
5
PUBM icon
PubMatic
PUBM
+$1.47M

Top Sells

Rank Stock Value
1
TRIL
Trillium Therapeutics Inc.
TRIL
+$8.18M
2
AFRM icon
Affirm
AFRM
+$2.92M
3
UPST icon
Upstart Holdings
UPST
+$2.87M
4
NUAN
Nuance Communications, Inc.
NUAN
+$2.06M
5
ATRA icon
Atara Biotherapeutics
ATRA
+$1.81M

Sector Composition

Rank Sector Weight
1 Healthcare 81.55%
2 Technology 7%
3 Communication Services 4.59%
4 Consumer Discretionary 2.09%
5 Energy 2.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GDRX icon
26
GoodRx Holdings
GDRX
$1.11B
$1.31M 0.94%
40,000
– –
ZETA icon
27
Zeta Global
ZETA
$6.75B
$1.14M 0.82%
135,000
– –
MTTR
28
DELISTED
Matterport, Inc. Class A Common Stock
MTTR
$1.14M 0.82%
55,000
-27,500
-33% -$630K
NGNE icon
29
Neurogene
NGNE
$718M
$1.02M 0.74%
10,625
-1,325
-11% -$161K
IMTX icon
30
Immatics
IMTX
$1.34B
$853K 0.62%
63,500
– –
UPST icon
31
Upstart Holdings
UPST
$2.89B
$847K 0.61%
5,600
-11,500
-67% -$2.87M
EIGR
32
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$823K 0.6%
5,283
– –
ONCT
33
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$817K 0.59%
18,000
– –
SURF
34
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$815K 0.59%
170,500
– –
COIN icon
35
Coinbase
COIN
$39.5B
$757K 0.55%
3,000
– –
CYPH
36
Cypherpunk Technologies Inc
CYPH
$78M
$729K 0.53%
22,500
+7,000
+45% +$194K
IMDX
37
Insight Molecular Diagnostics
IMDX
$161M
$716K 0.52%
16,500
– –
HLMN icon
38
Hillman Solutions
HLMN
$1.81B
$699K 0.51%
65,000
– –
AMZN icon
39
Amazon
AMZN
$2.94T
$667K 0.48%
4,000
-6,000
-60% -$1.03M
TGTX icon
40
TG Therapeutics
TGTX
$7.64B
$644K 0.47%
33,900
-26,100
-44% -$678K
NKTR icon
41
Nektar Therapeutics
NKTR
$2.47B
$621K 0.45%
3,067
-7,700
-72% -$1.67M
CRDF icon
42
Cardiff Oncology
CRDF
$74.3M
$616K 0.45%
102,500
– –
AVXL icon
43
Anavex Life Sciences
AVXL
$297M
$581K 0.42%
33,500
-37,000
-52% -$703K
CTRA
44
DELISTED
Coterra Energy
CTRA
$570K 0.41%
+30,000
New +$626K
CSBR icon
45
Champions Oncology
CSBR
$73.6M
$523K 0.38%
62,500
+4,000
+7% +$36.8K
GRTS
46
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$514K 0.37%
40,000
-34,000
-46% -$376K
PDSB icon
47
PDS Biotechnology
PDSB
$40.6M
$486K 0.35%
60,000
– –
FANG icon
48
Diamondback Energy
FANG
$52.4B
$485K 0.35%
+4,500
New +$488K
BTAI icon
49
BioXcel Therapeutics
BTAI
$26M
$407K 0.29%
1,250
-1,875
-60% -$805K
ONON icon
50
On Holding
ONON
$12.7B
$397K 0.29%
+10,500
New +$385K
1
2
3 4 5

Similar funds

BCI
Blue Capital Inc Omaha, Nebraska $153M AUM 28.69% 1-Year Est. Return
APW
Atlantic Private Wealth Chapel Hill, North Carolina $153M AUM 15.75% 1-Year Est. Return
DAM
Doheny Asset Management Los Angeles, California $153M AUM 42.04% 1-Year Est. Return
BVC
Bright Valley Capital Hong Kong $153M AUM 16.24% 1-Year Est. Return
RHAM
Round Hill Asset Management Pasadena, California $153M AUM 6.67% 1-Year Est. Return
RFN
Redwood Financial Network Solon, Ohio $153M AUM 17.17% 1-Year Est. Return
SGM
Sellaronda Global Management New York $152M AUM 2.1% 1-Year Est. Return
HWM
Horizons Wealth Management Asheville, North Carolina $152M AUM 9.43% 1-Year Est. Return

ACT Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, ACT Capital Management held 122 positions worth $138M, down 28% from $193M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

ACT Capital Management withdrew a net $14.6M in Q4 2021, closing 30 positions and reducing 28 holdings. Its most notable exit was Trillium Therapeutics Inc., an estimated $8.18M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 79% a quarter earlier, followed by Technology and Communication Services.

Against the trend, ACT Capital Management opened a new position in Meta Platforms (Facebook) worth $2.52M.

  • ACT Capital Management's largest Q4 2021 buy was Meta Platforms (Facebook): 7,500 shares worth $2.52M.
  • ACT Capital Management added most to Stratasys in Q4 2021, an estimated $1.84M increase.
  • ACT Capital Management's biggest Q4 2021 reduction was Upstart Holdings, cutting an estimated $2.87M.
  • ACT Capital Management fully exited Trillium Therapeutics Inc. in Q4 2021, selling an estimated $8.18M.
  • ACT Capital Management's ten largest holdings make up 61% of its $138M portfolio in Q4 2021.
  • ACT Capital Management opened 13 new positions and closed 30 in Q4 2021.
  • ACT Capital Management's portfolio value fell 28% quarter-over-quarter to $138M.

Based on ACT Capital Management's 13F filing for Q4 2021, filed 3 Feb 2022.